FDA grants accelerated approval for camizestrant in ESR1-mutated breast cancer

The FDA has accelerated approval for camizestrant with a CDK4/6 inhibitor in certain adults with HR-positive, HER2-negative advanced breast cancer that has an ESR1 mutation, based on SERENA-6 data. NHO Revive highlighted the decision as part of its ongoing involvement in camizestrant research across multiple breast cancer trials.

Why it matters: - The approval gives eligible patients a new treatment option after an ESR1 mutation is detected during aromatase inhibitor and CDK4/6 inhibitor therapy. - The FDA action is based on a progression-free survival benefit, which may delay disease worsening in advanced breast cancer. - Confirmatory studies are still required, so the decision is not the final word on clinical benefit.

What happened: - The FDA granted accelerated approval on Sept. 4, 2026, to camizestrant, also called Etcamah, for use with a CDK4/6 inhibitor. - The approval applies to certain adults with hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer with an ESR1 mutation detected by an FDA-authorized test. - NHO Revive said the decision reflects continued research into camizestrant and its potential use across breast cancer settings.

The details: - The FDA based the approval on results from the SERENA-6 clinical trial. - SERENA-6 evaluated switching to camizestrant when an ESR1 mutation was found before radiographic disease progression. - The FDA reported an estimated median progression-free survival of 16 months for camizestrant plus a CDK4/6 inhibitor, compared with 9.2 months for continued aromatase inhibitor plus a CDK4/6 inhibitor. - The accelerated approval pathway requires confirmatory studies to verify and describe clinical benefit. - NHO Revive previously conducted the SERENA-2 study. - NHO Revive is also participating in CAMBRIA-1 and CAMBRIA-2. - Those studies are evaluating camizestrant in advanced and early HR-positive, HER2-negative breast cancer.

Between the lines: - The FDA decision strengthens interest in biomarker-driven treatment changes, especially when resistance emerges during therapy. - NHO Revive’s role in multiple camizestrant studies signals continued site-level involvement in breast cancer research rather than a direct role in the approval itself. - The mention of separate studies suggests camizestrant is being tested beyond the newly approved setting.

What's next: - Confirmatory trials will determine whether the accelerated approval becomes a fully supported standard based on clinical benefit. - NHO Revive said it remains committed to supporting clinical research and helping eligible patients access trial opportunities. - Ongoing studies like CAMBRIA-1 and CAMBRIA-2 will continue evaluating camizestrant in additional breast cancer populations.

The bottom line: - Camizestrant now has an FDA-backed role in a defined ESR1-mutated breast cancer population, while broader research on the drug is still underway.

More information: the company’s announcement